Evaluating exosome multiomics and clinical outcomes in sudden cardiac death patients
Official title: Early Evaluation of Exosome Multiomics and Clinical Prognosis in Patients With Sudden Death
Run by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · NCT06856993 · Data updated 2026-11-12
This study looks at how certain tiny particles in the blood are connected to sudden cardiac death in patients who had symptoms before their heart stopped, to help improve future care and prevention.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Academic / other |
| Locations | 1 site (Nanjing, Jiangsu) |
| Status | Recruiting |
| Started | December 22, 2021 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2027 |
| Registry record updated | April 8, 2026 |
| Trial ID | NCT06856993 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older who have experienced sudden death with prior clinical symptoms and meet specific ACS diagnostic criteria.
✕Probably not a fit
Patients who died from accidental causes, chronic diseases, or natural causes are unlikely to benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the relationship between exosome multiomics and clinical prognosis in patients who experience sudden cardiac death (SCD), particularly in the context of acute coronary syndrome (ACS). It focuses on patients who have shown clinical symptoms prior to their sudden death and aims to gather data on the prevalence and characteristics of SCD in this population. The study will utilize standardized medical care protocols for cardiac arrest and analyze the collected data to improve understanding of SCD and its correlation with ACS. The findings may help inform future guidelines for prevention and treatment of ACS-related sudden death.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of sudden cardiac death and lead to improved prevention strategies for patients at risk.
How similar studies have gone: While there is limited research specifically on exosome multiomics in this context, studies on sudden cardiac death and acute coronary syndrome have shown promising results in understanding these conditions.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * The death event happens suddenly. * Age ≥ 18 years * The patient had obvious clinical symptoms 24 hours before treatment * Life expectancy exceeds 3 days * Proxy of patients signs the informed consent form * Comply with ACS diagnostic indicators recommended by ACC / AHA guidelines in 2016 Exclusion Criteria: * Death caused by accident, such as trauma, poisoning, etc. * Death from accidental or intentional overdose * Death from asphyxia * Death is caused by chronic disease or terminal illness * The patient died naturally * Has participated in other clinical studies * Immediate family members give up continuing treatment
Where it's running
-
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Predicting sudden cardiac arrest risk in people with coronary artery disease
This project will try to see if combining genetics, ECGs, blood biomarkers, imaging, and psychosocial information can predict which people with coronary artery disease are most likely to have sudden cardiac arrest.
-
Left bundle branch pacing plus ICD for people with hypertrophic cardiomyopathy after myectomy
This study will test whether adding left bundle branch pacing to a dual‑chamber ICD helps people with hypertrophic cardiomyopathy who develop left bundle branch block after myectomy to slow heart failure progression and prevent life‑threatening arrhythmias.
-
MSC exosome treatment to repair blood vessel damage after preeclampsia
This study will see if IV infusions of mesenchymal stem cell–derived exosomes help repair damaged blood vessels in women who recently had preeclampsia.
-
Carvedilol versus metoprolol succinate in people with heart failure and an implanted defibrillator
This study will test whether switching from metoprolol succinate to carvedilol reduces ICD therapies, heart-related hospitalizations, or cardiovascular death in adults with HFrEF and an ICD.
-
Understanding the connection between stroke and heart issues
This study is trying to understand how strokes affect heart health and overall well-being in stroke patients to find new ways to help them recover better.
-
Surgery to treat myocardial bridge in coronary arteries
This study tests if a special heart surgery can help people with symptoms from a condition called myocardial bridge feel better and improve their quality of life.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.